Search Results for:
-
AstraZeneca Reorganizes, Cuts 1,600 jobs, Ups the Ante in UK
While there are many interrelated causes, two of the main ones are a failure to make long-term investments in drug development pipelines and a hostile regulatory climate toward animal, especially rodent, research...Coming on top of the closure two years ago of Pfizer's R&D center in Sandwich, UK, where 2,400 people were employed, the announcement of at least 700 job losses at AstraZeneca "risks further reducing the UK's collective capability" in drug development, Downs saidBy Nuala Moran | BioWorld International | Wednesday, March 20, 2013 -
AstraZeneca Reorganizes, Cuts 1,600 jobs, Ups the Ante in UK
While there are many interrelated causes, two of the main ones are a failure to make long-term investments in drug development pipelines and a hostile regulatory climate toward animal, especially rodent, research...Coming on top of the closure two years ago of Pfizer's R&D center in Sandwich, UK, where 2,400 people were employed, the announcement of at least 700 job losses at AstraZeneca "risks further reducing the UK's collective capability" in drug development, Downs saidBy Nuala Moran | BioWorld Today | Tuesday, March 19, 2013 -
Multiple Strategies Employed To Build Early Stage Pipelines
The academic PI sits on the drug development team, so instead of hiring a key opinion leader to come in once a year and tell us whether we're doing a good job, we usually have the expert in that pathway, in that biology, in that target, someone who's worked on it for decades, actually sitting on our drug development team," Lindberg saidBy Brian Orelli | BioWorld Insight | Monday, March 18, 2013 -
Word on the Street
This is certainly good news for the pharmaceutical industry and biotechs that are active in AD drug developmentBioWorld Insight | Monday, March 18, 2013 -
FDA's Draft Guidance Changes Game in Early Alzheimer's
This is certainly good news for the pharmaceutical industry and biotechs that are active in AD drug development...Biomarker Development Following the Science The FDA makes clear, however, that there's no getting around the need for biomarker development to go hand in hand with drug development in early ADBy Marie Powers | BioWorld Today | Friday, March 15, 2013 -
Other News To Note
Sunshine Biopharma Inc., of Montreal, said it started negotiations with several contract manufacturing organizations for the GMP manufacturing of 1 kg of Adva-27a, its drug in development for treating breast cancer that has become resistant to existing therapeuticsBioWorld Today | Friday, March 15, 2013 -
FDA Adds Ampligen Experts To Roster for CFS Workshop
The FDA published a notice in the Federal Register about the public workshop called "Drug Development for Chronic Fatigue Syndrome...It's the first such workshop held as part of the Patient-Focused Drug Development initiative, mandated in the authorization of the Prescription Drug User Fee Act, and a prime topic, given the uproar over the agency's refusal to approve Ampligen (rintatolimod) after a negative advisory panel meeting in December. (See BioWorld Today, Dec. 21, 2012.) Ampligen was theBy Randy Osborne | BioWorld Today | Thursday, March 14, 2013 -
GSK Closing Sirtris Lab, Moving Research In-House
Changes in the scientific understanding of how to modulate SIRT1 could affect drug development timetables, according to an analysis of the paper scheduled for the March 18 issue of BioWorld InsightBy Marie Powers | BioWorld Today | Thursday, March 14, 2013 -
Other News To Note
Founded in 2007, Auven is structured as a private equity fund that also operates as a drug development companyBioWorld Today | Tuesday, March 12, 2013 -
Week in Washington
The Reproductive Health Drugs and the Drug Safety and Risk Management advisory committees voted 20-1 that sponsors of calcitonin drugs in development should be required to submit fracture efficacy data for approvalBioWorld Insight | Monday, March 11, 2013 -
Emerging Markets Slow-Going, Not Near Threat, Data Confirm
The first signs surfaced in about 2007 that maybe China and India would not soon become the drug-development giants that the U.SBy Randy Osborne | BioWorld Today | Monday, March 11, 2013 -
Other News To Note
Zhangjiang Biotech Pharmaceutical Base will be able to consult with HUYA's experts in drug development and commercialization, while HUYA will have the first opportunity to evaluate certain R&D projects conducted at the baseBioWorld Today | Thursday, March 7, 2013 -
FDA Workshop Examines CFS; Hope for Hemispherx, Patients?
Repurposing approved drugs – many of which already are being used for symptom relief – to give them official labels for chronic fatigue syndrome (CFS) will be one topic at an FDA-sponsored workshop next month on drug development for CFS and myalgic encephalomyelitis (MEBy Randy Osborne | BioWorld Today | Thursday, March 7, 2013 -
Adcoms Recommend Higher Standards for Calcitonin Drugs
The Reproductive Health Drugs and the Drug Safety and Risk Management advisory committees voted 20-1 that sponsors of calcitonin drugs in development should be required to submit fracture efficacy data for approvalBy Mari Serebrov | BioWorld Today | Wednesday, March 6, 2013 -
Other News To Note
QIDP designation is under the GAIN Act included in the 2012-passed FDASIA legislation and is designed to provide drug development with incentives for creating new antibacterial and antifungal drugsBioWorld Today | Monday, March 4, 2013 -
Week in Review
Deals 4SC AG signed a preclinical drug development deal in inflammatory skin disease with Leo Pharma A/S. Ablynx NV and Spirogen LtdBioWorld Insight | Monday, March 4, 2013 -
Word on the Street
I have to confess, it is very difficult to break from the classic paradigm of single-target drug development." – Winston Ko, chairman and CEO of Genervon Biopharmaceuticals IncBioWorld Insight | Monday, March 4, 2013 -
Genervon Tackling Tough CNS Space via Multitarget Approach
The problem is that the traditional drug development approach of designing single-target drugs for CNS diseases simply hasn't worked, said Winston Ko, chairman and CEO of Genervon Biopharmaceuticals Inc., a firm he founded in 2002 to develop MNTF, a family of nine master regulators of the CNS...I have to confess, it is very difficult to break from the classic paradigm of single-target drug development," he saidBy Jennifer Boggs | BioWorld Today | Thursday, February 28, 2013 -
Industry-Academic Research Gets $261M Boost in Ireland
Although three of the seven centers are focused on life sciences – and a fourth has a significant life sciences strand – none will perform discovery research leading to drug development, although Science Foundation Ireland (SFI) continues to fund basic life sciences research through its principal investigators programBy Cormac Sheridan | BioWorld International | Wednesday, February 27, 2013 -
4SC, Leo Pharma Ink $125M Preclinical Deal in Psoriasis
4SC AG could earn up to €96 million (US$125 million) in option and milestone payments arising out of a preclinical drug development deal in inflammatory skin disease with Leo Pharma A/S, as well as double-digit royalties on eventual product salesBy Cormac Sheridan | BioWorld International | Wednesday, February 27, 2013
Category
Current Filters
- xdrug development
Related Keywords
Categories
- x BioWorld Today (2529)
- x BioWorld International (621)
- x BioWorld Insight (357)
- x Bio Perspectives (145)
- x BioWorld Genomics Review (91)
- x State of the Industry Report (58)
- x Top 25 Drug Report (38)
- x BioWorld Snapshots (29)
- x RNAi Report (11)
- x Biotech Innovations (10)
- x Market-Leading Biotech Drugs (4)
- x Executive Compensation Report (3)
- x Recorded (2)
- x Featured (1)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.